Products KW-2478 + Bortezomib
KW-2478 + Bortezomib Phase 1/2 Completed ⚡ Active Mar 1, 2010 → Nov 1, 2013
About KW-2478 + Bortezomib KW-2478 + Bortezomib is a phase 1/2 stage product being developed by Kyowa Kirin for Multiple Myeloma. The current trial status is completed. This product is registered under clinical trial identifier NCT01063907. Target conditions include Multiple Myeloma.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT01063907 Phase 1/2 Completed Mar 1, 2010 Nov 1, 2013 Multiple Myeloma
Product Company Stage Hype Score Placebo + Pirtobrutinib Eli Lilly Phase 2 Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 NEX-20A Nanexa AB Phase 1 agenT-797 MiNK Therapeutics Phase 1 Duloxetine Hydrochloride (HCI) + Placebo Eli Lilly Phase 3 Temferon Genenta Science Phase 1/2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 CT-P53 + US-Ocrevus + EU-Ocrevus Celltrion Phase 3 CS-0777 tablets + CS-0777 tablets + CS-0777 tablets Daiichi Sankyo Phase 1 ASP7487, Velcade, Dexamethasone Astellas Pharma Phase 1/2 PHE885 Novartis Phase 2 Mirabegron + Placebo Astellas Pharma Approved Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + Placebo Astellas Pharma Approved Denileukin Diftitox (Ontak) Eisai Phase 1 Palonosetron Eisai Phase 2 BIW-8962 Kyowa Kirin Phase 1 KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor) Kyowa Kirin Phase 2 ONO-2808 + Placebo Ono Pharmaceutical Phase 2 KW-2478 Kyowa Kirin Phase 1 ONO-4641 + ONO-4641 + ONO-4641 + ONO-4641 placebo Ono Pharmaceutical Phase 2
Other Products from Kyowa Kirin